The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment

Basit Öğe Kaydı
dc.authorid0000-0002-5853-5150
dc.authorid0000-0001-6915-0283
dc.authorid0000-0002-2088-9914
dc.authorid0000-0002-4569-008X
dc.authorid0000-0002-7911-8372
dc.authorid0000-0002-1783-7275
dc.contributor.authorÖzsoy, Münteha
dc.contributor.authorPirinçci Tok, Yağmur
dc.contributor.authorGüney Eskiler, Gamze
dc.contributor.authorTok, Fatih
dc.contributor.authorKarakuş, Sevgi
dc.contributor.authorÖzsoy, Yıldız
dc.contributor.authorÖzaçar, Mahmut
dc.date.accessioned2025-05-04T11:07:14Z
dc.date.available2025-05-04T11:07:14Z
dc.date.issued2025
dc.departmentFakülteler, Eczacılık Fakültesi, Eczacılık Teknoloji Bölümü, Farmasötik Teknoloji Ana Bilim Dalı
dc.description.abstractLenalidomide (L0) is an immunomodulatory agent with a range of effects, including anticancer and anti-inflammatory activity, and is commonly utilized in treating multiple myeloma. A derivative of lenalidomide (L1) has been synthesized to enhance its effects and to target different cancer cell types. In this study, the lenalidomide derivative L1, with the chemical structure 1-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]-3-(p-tolyl)urea, was loaded onto a novel drug delivery system (DDS), and its activity was assessed towards triple-negative breast cancer cell lines (TNBC). MIL-100, a subclass of metal-organic framework (MOF) structures, was synthesized via a microwave-assisted hydrothermal method. MIL-100 was modified with quercetin (QC) as a linker, and its drug loading capacity was optimized, achieving a 95.18 % encapsulation efficiency. Additionally, the antioxidant properties of QC contributed to enhancing the performance of the DDS. In vitro drug release studies of the final product, MIL-100@QC@L1, were successfully conducted. The cytotoxic influences of the formulation on MDA-MB-231 cells were assessed using the WST-1 assay. After treatment with 10 μg/mL of MIL-100@QC@L1 for 24 h, the cell viability decreased significantly to 47.8 %, showing superior results compared to treatments with L0 and L1 alone.
dc.identifier.citationÖzsoy, M., Pirinçci Tok, Y., Güney Eskiler, G., Tok, F., Karakuş, S., Özsoy, Y., & Özaçar, M. (2025). The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment. Journal of Drug Delivery Science and Technology, 108, pp. 1-11. https://doi.org/10.1016/j.jddst.2025.106923
dc.identifier.doi10.1016/j.jddst.2025.106923
dc.identifier.endpage11
dc.identifier.issn1773-2247
dc.identifier.scopus2-s2.0-105002790763
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2025.106923
dc.identifier.urihttps://hdl.handle.net/20.500.13055/973
dc.identifier.volume108
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorPirinçci Tok, Yağmur
dc.institutionauthorid0000-0001-6915-0283
dc.language.isoen
dc.publisherEditions de Sante
dc.relation.ispartofJournal of Drug Delivery Science and Technology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug Delivery System
dc.subjectLenalidomide-Like Novel Drug Derivative
dc.subjectMIL-100 (Fe)
dc.subjectQuercetin
dc.subjectTriple Negative Breast Cancer
dc.titleThe lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text
Boyut:
8.72 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Farmasötik Teknoloji Ana Bilim Dalı Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu